Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019.

Literature DB >> 34893821

Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019.

Jeremy A W Gold¹, Seda S Tolu², Tom Chiller¹, Kaitlin Benedict¹, Brendan R Jackson¹.

Abstract

We analyzed administrative data to determine the 1-year incidence of invasive fungal infections (IFIs) in patients beginning small molecule kinase inhibitor (SMKI) therapy. The incidence of IFIs by small molecule kinase inhibitor ranged from 0.0% to 10.6%, with patients taking midostaurin having the highest incidence. An IFI developed in 38 of 1286 patients taking ibrutinib (3.0%). Published by Oxford University Press for the Infectious Diseases Society of America 2021.

Entities: Chemical

Keywords: cancer; ibrutinib; invasive fungal infections; opportunistic infections; small molecule kinase inhibitors

Mesh：

Substances：

Year: 2022 PMID： 34893821 PMCID： PMC9184298 DOI： 10.1093/cid/ciab1026

Source DB: PubMed Journal: Clin Infect Dis ISSN： 1058-4838 Impact factor: 20.999

10 in total

1. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.

Authors: David Ghez; Anne Calleja; Caroline Protin; Marine Baron; Marie-Pierre Ledoux; Gandhi Damaj; Mathieu Dupont; Brigitte Dreyfus; Emmanuelle Ferrant; Charles Herbaux; Kamel Laribi; Ronan Le Calloch; Marion Malphettes; Franciane Paul; Laetitia Souchet; Malgorzata Truchan-Graczyk; Karen Delavigne; Caroline Dartigeas; Loïc Ysebaert
Journal: Blood Date: 2018-02-01 Impact factor: 22.113

Review 2. How I treat CLL patients with ibrutinib.

Authors: Jennifer R Brown
Journal: Blood Date: 2017-12-18 Impact factor: 22.113

3. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.

Authors: Tilly Varughese; Ying Taur; Nina Cohen; M Lia Palomba; Susan K Seo; Tobias M Hohl; Gil Redelman-Sidi
Journal: Clin Infect Dis Date: 2018-08-16 Impact factor: 9.079

4. Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib.

Authors: Thomas Holowka; Harry Cheung; Maricar Malinis; Geliang Gan; Yanhong Deng; Sarah Perreault; Iris Isufi; Marwan M Azar
Journal: J Infect Chemother Date: 2021-08-11 Impact factor: 2.065

5. Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.

Authors: Georgios Chamilos; Michail S Lionakis; Dimitrios P Kontoyiannis
Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 9.079

6. Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.

Authors: Rosa Ruchlemer; Ronen Ben-Ami; Maskit Bar-Meir; Jennifer R Brown; Marion Malphettes; Rogier Mous; Sanne H Tonino; Carole Soussain; Noelie Barzic; Julia A Messina; Preetesh Jain; Regev Cohen; Brian Hill; Stephen P Mulligan; Marcel Nijland; Yair Herishanu; Ohad Benjamini; Tamar Tadmor; Koh Okamoto; Benjamin Arthurs; Batsheva Gottesman; Arnon P Kater; Munir Talha; Barbara Eichhorst; Maya Korem; Naama Bogot; Fransien De Boer; Jacob M Rowe; Tamar Lachish
Journal: Mycoses Date: 2019-10-22 Impact factor: 4.377

1 in total

1. Case Commentary: Long-Term Fosmanogepix Use in a Transplant Recipient with Disseminated Aspergillosis Caused by Azole-Resistant Aspergillus calidoustus.

Authors: Ahnika Kline; Michail S Lionakis
Journal: Antimicrob Agents Chemother Date: 2022-01-24 Impact factor: 5.938

1 in total

Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019.

1. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.

Review 2. How I treat CLL patients with ibrutinib.

3. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.

4. Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib.

5. Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.

6. Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.

7. Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors.

8. Invasive fungal infections in high-risk patients: report from TIMM-8 2017.

Review 9. Trends in kinase drug discovery: targets, indications and inhibitor design.

Review 10. Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma.

1. Case Commentary: Long-Term Fosmanogepix Use in a Transplant Recipient with Disseminated Aspergillosis Caused by Azole-Resistant Aspergillus calidoustus.